GPCR

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

Domain Therapeutics Further Strengthens Leadership Team With Appointment of Sean A. MacDonald as Chief Business Officer

Retrieved on: 
Thursday, February 8, 2024

Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the appointment of Sean A. MacDonald as its Chief Business Officer (CBO) and member of the executive management team.

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the appointment of Sean A. MacDonald as its Chief Business Officer (CBO) and member of the executive management team.
  • Over the past year, Sean worked with Domain as an independent Senior Advisor, providing strategic input and support to the Company’s management team.
  • This included positions such as Chief Business Officer of iOnctura, Head of Business Development for Cosmo Pharmaceuticals, President and Chief Executive Officer of Corbin Therapeutics Inc, and Vice President of Corporate and Business development at Pharmascience Inc.
  • Dr. Tony Johnson, President and Chief Executive Officer of Domain Therapeutics, said: “This is an incredible time for Domain Therapeutics, and as the Company continues to grow, I am thrilled to officially welcome Sean to the team.

Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of Directors

Retrieved on: 
Tuesday, February 6, 2024

Dr. Coulie and Ms. Sharp bring deep drug development and company-building experience to Septerna’s board.

Key Points: 
  • Dr. Coulie and Ms. Sharp bring deep drug development and company-building experience to Septerna’s board.
  • Shalini brings a wealth of strategic, financial, and operational experience, having led or advised several successful private and public biotech companies.
  • Bernard Coulie brings more than two decades of senior leadership experience and drug development expertise to the Septerna board.
  • Shalini Sharp has been in the life sciences industry for over 25 years, having spent 14 years as a Chief Financial Officer.

Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation

Retrieved on: 
Thursday, February 1, 2024

Edinburgh, Scotland, 1 February 2024 – Cumulus Oncology (a biotech creation company) today proudly unveils the inauguration of GIO Therapeutics AG, based in Basel, Switzerland.

Key Points: 
  • Edinburgh, Scotland, 1 February 2024 – Cumulus Oncology (a biotech creation company) today proudly unveils the inauguration of GIO Therapeutics AG, based in Basel, Switzerland.
  • This newly established biotech company specialises in the development of pharmaceuticals targeting G protein-coupled receptors (GPCR).
  • Heading GIO Therapeutics is Dr Xavier Leroy who has been appointed as Chief Executive Officer.
  • Dr Xavier Leroy, CEO of GIO Therapeutics commented: “While GPCRs are well-known drug targets, their potential in cancer therapeutics is currently underutilised.

AVROBIO and Tectonic Therapeutic Announce Merger

Retrieved on: 
Tuesday, January 30, 2024

AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the “Merger”).

Key Points: 
  • AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the “Merger”).
  • Under the terms of the agreement, AVROBIO will acquire 100% of the outstanding equity interests of Tectonic.
  • The private placement is expected to close in conjunction with the Merger in the second quarter of 2024.
  • “We are delighted to merge with AVROBIO at this important time for Tectonic.

Maxion Therapeutics Welcomes Dr Arndt Schottelius as New CEO

Retrieved on: 
Thursday, February 1, 2024

Arndt has extensive experience in discovery, project and portfolio management, preclinical and clinical development, FDA negotiations and regulatory filings as well as business development.

Key Points: 
  • Arndt has extensive experience in discovery, project and portfolio management, preclinical and clinical development, FDA negotiations and regulatory filings as well as business development.
  • Eva-Lotta Allan, Chair of the Board of Directors commented: "It is with great pleasure that I, on behalf of the Board, welcome Arndt to Maxion.
  • Dr Arndt Schottelius, incoming CEO said: "Maxion's truly revolutionary technology has the unique opportunity to deliver first-in-class and best-in-class protein therapeutics to treat ion channel and GPCR-driven diseases.
  • I am delighted to join Maxion Therapeutics at such an exciting time in the Company's development.

Domain Therapeutics Awarded Hospital-University Research in Health (RHU) SPRINT Consortium Grant to Progress Its Proprietary CCR8 Antibody Candidate to the Clinic

Retrieved on: 
Thursday, January 25, 2024

Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces it has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium.

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces it has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium.
  • View the full release here: https://www.businesswire.com/news/home/20240125583037/en/
    The SPRINT project aims to revolutionize the management of patients with CTCL and deliver a new cure paradigm as a standard-of-care.
  • The grant that we have been awarded by the RHU SPRINT consortium will support the progress of DT-7012, an anti-CCR8 monoclonal antibody which has incredible potential as a best-in-class therapeutic, into the clinic.
  • Domain was already awarded a first RHU grant, RHU CONDOR for Sarcoma, in the previous campaign, leveraging another proprietary asset.

Adimab Announces Substantial Expansion of Research Campus

Retrieved on: 
Wednesday, January 10, 2024

Over the past seven years, Adimab has added more than 400 royalty bearing therapeutic programs.

Key Points: 
  • Over the past seven years, Adimab has added more than 400 royalty bearing therapeutic programs.
  • To accommodate this continual growth, Adimab has increased headcount by approximately 40% over the past three years.
  • “We have not expanded the footprint of our main research facility since initially occupying it in 2011,” explained Eric Krauland, President and Chief Scientific Officer of Adimab.
  • Antibodies from Adimab have exquisite specificity and are utilized as monospecific and multispecific therapies as well as CAR-Ts, ADCs, and other proteins.

Domain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology Company

Retrieved on: 
Monday, January 8, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240108886645/en/
    Michael’s appointment as Chairman follows Laurence Rulleau and Youssef Bennani, who held the role for 9 years.
  • An industry expert with international experience leading biopharmaceutical companies, Michael is also currently the President and Chief Executive Officer of RENOGENYX.
  • As the new President and CEO, based in Boston, Tony succeeds Pascal Neuville who founded and successfully led the Company for the past 15 years.
  • Their respective expertise and track record in pioneering and leading biopharmaceutical companies will be invaluable to the Company and will support our reach and global focus.

Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO

Retrieved on: 
Wednesday, January 3, 2024

Radionetics Oncology, Inc. , a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, announces the completion of a $52.5 million Series A financing.

Key Points: 
  • Radionetics Oncology, Inc. , a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, announces the completion of a $52.5 million Series A financing.
  • Radionetics plans to use the proceeds to advance its pipeline of potent, small molecule radiopharmaceuticals targeting novel G-protein coupled receptors (GPCRs) for the treatment of a broad range of cancers.
  • He was most recently the President and CEO of Tentarix Biotherapeutics, an oncology company focused on multi-functional biologics.
  • “The spatial biology and pharmacology of GPCRs makes them ideal for small molecule radiopharmaceutical development, opening a new chapter for the field.”